Kestra Medical Technologies raised its fiscal 2027 revenue guidance to $141 million from a prior $137 million, representing 48% growth over fiscal 2026, after first-quarter revenue grew 60% year-over-year to $31 million. Gross margin rose to 56.5% from 45.7% a year earlier, which CEO Brian Webster said marked the 11th consecutive quarter of sequential gross margin expansion. Webster also lifted the company's longer-term gross margin target to the mid-70s within the next few years, a meaningful increase from the previously communicated 70% goal. CFO Vaseem Mahboob attributed the quarter to continued WCD market expansion, competitive share gains, a higher mix of in-network patients and improvements in revenue cycle management, and said the second half of the year should be faster than the first as sales representatives ramp up. The quarter included a GAAP net loss of $44.1 million and an adjusted EBITDA loss of $24 million, while cash, cash equivalents and investments totaled $245 million, with liquidity of approximately $320 million including a new $200 million term loan facility announced in July.
Kestra Medical Technologies, Ltd. Common StockKestra raised FY2027 revenue guidance to $141M and reported Q1 revenue up 60% to $31M with gross margin expanding to 56.5%.
